Simtuzumab is used for research in primary sclerosing cholangitis (PSC); it has been investigated for the treatment of idiopathic pulmonary fibrosis (IPF) by targeting lysyl oxidase-like protein 2 (LOXL2) to disrupt the fibrotic cycle, reduce fibroblast activation, decrease growth factor production, and downregulate TGF-β.